{"disease":{"id":"reti","name":"reti"},"drugs":{"marketed":[{"drug_id":"aflibercept","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"aflibercept","indication_name":"Retinopathy of prematurity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"aflibercept","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"tafamidis","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":"1430.0","mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"tafamidis","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":"1430.0","mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"lanreotide","indication_name":"Thyroid-stimulating hormone secreting pituitary tumour","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Somatuline Depot","generic_name":"LANREOTIDE","company_name":"Ipsen Pharma","drug_phase":"marketed","molecular_target":"Somatostatin receptor type 2","drug_class":"Somatostatin Analog","quality_score":10,"revenue":"1200","mechanism":"Somatuline Depot works by mimicking the natural hormone somatostatin to block the production of excess growth hormone."},{"drug_id":"tolvaptan","indication_name":"Syndrome of inappropriate vasopressin secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Samsca","generic_name":"TOLVAPTAN","company_name":"Otsuka","drug_phase":"marketed","molecular_target":"Vasopressin V2 receptor","drug_class":"Vasopressin V2 Receptor Antagonist [EPC]","quality_score":80,"revenue":"1200","mechanism":"Samsca works by blocking the action of vasopressin, a hormone that regulates water levels in the body."},{"drug_id":"vutrisiran","indication_name":"Transthyretin familial amyloid polyneuropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amvuttra","generic_name":"VUTRISIRAN","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"transthyretin (TTR) mRNA","drug_class":"Small Interfering RNA","quality_score":10,"revenue":"1100","mechanism":"Amvuttra works by silencing the production of abnormal TTR protein through RNA interference."},{"drug_id":"cyclophosphamide","indication_name":"Retinoblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"patisiran","indication_name":"Transthyretin familial amyloid polyneuropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onpattro","generic_name":"PATISIRAN","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"transthyretin (TTR) mRNA","drug_class":"Small Interfering RNA","quality_score":59,"revenue":"700","mechanism":"Onpattro works by silencing the production of abnormal TTR protein using small interfering RNA."},{"drug_id":"patisiran-sodium","indication_name":"Transthyretin familial amyloid polyneuropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onpattro","generic_name":"PATISIRAN SODIUM","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"transthyretin (TTR) mRNA","drug_class":"Small Interfering RNA","quality_score":10,"revenue":"700","mechanism":"Onpattro works by silencing the production of abnormal TTR protein through RNA interference."},{"drug_id":"lonapegsomatropin","indication_name":"Growth failure due to inadequate secretion of endogenous growth hormone (GH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Skytrofa","generic_name":"LONAPEGSOMATROPIN","company_name":"Ascendis Pharma Encocrinology Div A/S","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant Human Growth Hormone [EPC]","quality_score":10,"revenue":"446","mechanism":"Skytrofa works by mimicking the natural growth hormone to stimulate growth in individuals with growth hormone deficiency."},{"drug_id":"potassium-bicarbonate","indication_name":"Prevention of Potassium Depletion - Digitalis and Diuretics","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"POTASSIUM BICARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"sulfur-colloid","indication_name":"Imaging reticuloendothelial cells","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sulfur Colloid","company_name":"University of California, San Diego","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":"Technetium Tc 99m Sulfur Colloid is used for imaging by entering lymphatic capillaries, mixing with peritoneal fluid, or being taken up by the reticuloendothelial system."},{"drug_id":"sulfur-colloid","indication_name":"Imaging reticuloendothelial cells","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sulfur Colloid","company_name":"University of California, San Diego","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":"Technetium Tc 99m Sulfur Colloid is used for imaging by entering lymphatic capillaries, mixing with peritoneal fluid, or being taken up by the reticuloendothelial system."},{"drug_id":"vyndaqel","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis Meglumine","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin (TTR)","drug_class":"Transthyretin stabilizer","quality_score":10,"revenue":null,"mechanism":"Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation."},{"drug_id":"vyndaqel","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis Meglumine","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin (TTR)","drug_class":"Transthyretin stabilizer","quality_score":10,"revenue":null,"mechanism":"Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation."},{"drug_id":"acetadote","indication_name":"Thick Bronchial Secretions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Acetadote","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"verteporfin","indication_name":"Choroidal retinal neovascularization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Visudyne","generic_name":"VERTEPORFIN","company_name":"Bausch Lomb Ireland","drug_phase":"marketed","molecular_target":"","drug_class":"Photoenhancer [EPC]","quality_score":10,"revenue":null,"mechanism":"Visudyne selectively binds to neovascular tissue, which is then activated by light to induce a phototoxic reaction."},{"drug_id":"sulfadiazine","indication_name":"Chorioretinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfadiazine","generic_name":"SULFADIAZINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Sulfonamide Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-test","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis-test","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"tafamidis-test","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis-test","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"dexamethasone","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"iodinated-glycerol","indication_name":"Thick Bronchial Secretions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Organidin","generic_name":"iodinated glycerol","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Organidin works by helping to thin and loosen mucus in the airways, making it easier to cough up."},{"drug_id":"visudyne","indication_name":"Choroidal retinal neovascularization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Visudyne","company_name":"Bayer","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"acetylcysteine","indication_name":"Thick Bronchial Secretions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acetadote","generic_name":"Acetylcysteine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Glutathione levels; reactive metabolite of acetaminophen","drug_class":"Antidote","quality_score":62,"revenue":null,"mechanism":"Acetylcysteine reduces liver injury from acetaminophen overdose by maintaining glutathione levels or providing alternate conjugation substrate."},{"drug_id":"cyclophosphamid","indication_name":"Retinoblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"acetylcystein","indication_name":"Thick Bronchial Secretions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Acetylcystein","company_name":"University Hospital, Strasbourg, France","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"eylea","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"eylea","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"eylea","indication_name":"Retinopathy of prematurity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"lonapegsomatropin-tcgd","indication_name":"Growth failure due to inadequate secretion of endogenous growth hormone (GH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SKYTROFA","generic_name":"LONAPEGSOMATROPIN-TCGD","company_name":"ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S","drug_phase":"marketed","molecular_target":"growth hormone (GH) receptor","drug_class":"Recombinant Human Growth Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":"SKYTROFA binds to the GH receptor, triggering signal transduction and various pharmacodynamic effects, including growth stimulation in pediatric GHD."},{"drug_id":"lucentis","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lucentis","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lucentis","indication_name":"Choroidal retinal neovascularization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lucentis","indication_name":"Diabetic retinopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lucentis","indication_name":"Retinopathy of prematurity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"calcium-dobesilate","indication_name":"Diabetic retinopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexium","generic_name":"CALCIUM DOBESILATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"calcium dobesilate","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"acoramidis","indication_name":"cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Attruby","generic_name":"ACORAMIDIS","company_name":"Bridgebio Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Attruby works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"secretin-human","indication_name":"Secretin Stimulation Testing","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chirhostim","generic_name":"Secretin Human","company_name":"Chirhoclin","drug_phase":"marketed","molecular_target":"Secretin receptor","drug_class":"Secretin-class Hormone","quality_score":10,"revenue":null,"mechanism":"Chirhostim works by binding to the secretin receptor, mimicking the natural hormone secretin to stimulate pancreatic function."},{"drug_id":"l-cysteine","indication_name":"Thick Bronchial Secretions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"vyndamax","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vyndamax","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils."},{"drug_id":"valganciclovir","indication_name":"CMV Retinitis in AIDS Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valcyte","generic_name":"VALGANCICLOVIR","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Valcyte works by inhibiting the replication of cytomegalovirus DNA through its action as a nucleoside analog DNA polymerase inhibitor."},{"drug_id":"cidofovir","indication_name":"CMV Retinitis in AIDS Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vistide","generic_name":"CIDOFOVIR","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"cidofovir","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"sermorelin","indication_name":"Diagnostic Test for Growth Hormone Secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geref","generic_name":"sermorelin","company_name":"","drug_phase":"marketed","molecular_target":"Growth hormone-releasing hormone receptor","drug_class":"sermorelin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"milrinone-lactate","indication_name":"Acute decompensated heart failure in patients receiving diuretics","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Milrinone Lactate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Phosphodiesterase-3 (PDE-3) enzyme","drug_class":"Inotropic agent; Phosphodiesterase-3 inhibitor; Vasodilator","quality_score":66,"revenue":null,"mechanism":"Phosphodiesterase-3 inhibitor that increases cardiac contractility and promotes vasodilation through cAMP elevation."},{"drug_id":"arginine","indication_name":"Diagnostic Test for Growth Hormone Secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"R-Gene 10","generic_name":"ARGININE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nitric oxide synthase, inducible","drug_class":"arginine hydrochloride","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isoprenaline","indication_name":"Thick Bronchial Secretions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isuprel","generic_name":"isoprenaline","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta-Adrenergic Agonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ganciclovir","indication_name":"CMV Retinitis in AIDS Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"prednisone","indication_name":"Chorioretinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ganciclovir","indication_name":"Cytomegaloviral retinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"probenecid","indication_name":"Adjunct Treatment to Inhibit Renal Drug Excretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Col-Probenecid","generic_name":"probenecid","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 9","drug_class":"probenecid","quality_score":10,"revenue":null,"mechanism":"ORLYNVAH combines sulopenem etzadroxil, a penem antibacterial, with probenecid to increase sulopenem's plasma concentration by inhibiting its renal clearance."},{"drug_id":"eplontersen","indication_name":"polyneuropathy of hereditary transthyretin-mediated amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wainua","generic_name":"EPLONTERSEN","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"","drug_class":"Transthyretin-directed RNA Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Wainua works by binding to the transthyretin RNA to prevent the production of the transthyretin protein."},{"drug_id":"cysteine","indication_name":"Thick Bronchial Secretions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cysteine Hydrochloride","generic_name":"CYSTEINE","company_name":"Exela Pharma","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Vitamin C [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"fomivirsen","indication_name":"Cytomegaloviral retinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FOMIVIRSEN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"fomivirsen","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"foscarnet","indication_name":"CMV Retinitis in AIDS Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foscavir","generic_name":"FOSCARNET","company_name":"Clinigen Hlthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrophosphate Analog DNA Polymerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Foscarnet works by directly inhibiting viral DNA polymerase, preventing the replication of viral DNA."},{"drug_id":"chembl-chembl1200796","indication_name":"Retinoblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"vistide","indication_name":"CMV Retinitis in AIDS Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vistide","company_name":"Gustave Roussy, Cancer Campus, Grand Paris","drug_phase":"marketed","molecular_target":"DNA polymerase catalytic subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ranibizumab-nuna","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-nuna","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-nuna","indication_name":"Choroidal retinal neovascularization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-nuna","indication_name":"Diabetic retinopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-nuna","indication_name":"Retinopathy of prematurity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ganciclovir","indication_name":"CMV Retinitis in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"somatrogon","indication_name":"Growth failure due to inadequate secretion of endogenous growth hormone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ngenla","generic_name":"somatrogon","company_name":"Pfizer Ireland Pharmaceuticals","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Ngenla works by binding to the growth hormone receptor, mimicking the action of natural growth hormone."},{"drug_id":"hyoscyamine","indication_name":"Gastric Secretion Control","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(-)-Atropine","generic_name":"Hyoscyamine","company_name":"University of Kansas Medical Center","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"hyoscyamine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-eqrn","indication_name":"Macular Edema Following Retinal Vein Occlusion (RVO)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-eqrn","indication_name":"Diabetic Retinopathy (DR)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Chorioretinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"somapacitan-beco","indication_name":"Growth failure due to inadequate GH secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SOGROYA","generic_name":"SOMAPACITAN-BECO","company_name":"NOVO NORDISK INC","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"eplontersen","indication_name":"Polyneuropathy of hereditary transthyretin-mediated amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wainua","generic_name":"EPLONTERSEN","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"","drug_class":"Transthyretin-directed RNA Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Wainua works by binding to the transthyretin RNA to prevent the production of the transthyretin protein."},{"drug_id":"foscarnet","indication_name":"CMV Retinitis in AIDS Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foscavir","generic_name":"FOSCARNET","company_name":"Clinigen Hlthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrophosphate Analog DNA Polymerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Foscarnet works by directly inhibiting viral DNA polymerase, preventing the replication of viral DNA."},{"drug_id":"foscarnet","indication_name":"CMV Retinitis Relapse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foscavir","generic_name":"FOSCARNET","company_name":"Clinigen Hlthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrophosphate Analog DNA Polymerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Foscarnet works by directly inhibiting viral DNA polymerase, preventing the replication of viral DNA."},{"drug_id":"somapacitan","indication_name":"Growth failure due to inadequate GH secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."},{"drug_id":"chembl-chembl4297830","indication_name":"Growth failure due to inadequate growth hormone secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SOMATROGON","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"vyndamax-tafamidis-61mg","indication_name":"ATTR-CM (Transthyretin Amyloid Cardiomyopathy)","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndamax (tafamidis 61mg)","generic_name":"vyndamax-tafamidis-61mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"As prescribed in real world practice","quality_score":0,"revenue":null,"mechanism":"As prescribed in real world practice"},{"drug_id":"treatment-for-ttr-amyloidosis","indication_name":"Transthyretin (TTR) Amyloid Cardiomyopathy","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treatment for TTR amyloidosis","generic_name":"treatment-for-ttr-amyloidosis","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if n","quality_score":null,"revenue":null,"mechanism":"The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if n"},{"drug_id":"tafamidis-61-milligrams","indication_name":"Transthyretin Amyloid Cardiomyopathy","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis 61 milligrams","generic_name":"tafamidis-61-milligrams","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Tafamidis 61mg as provided in real-world practice","quality_score":null,"revenue":null,"mechanism":"Tafamidis 61mg as provided in real-world practice"}],"offLabel":[],"totalMarketed":77,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT04678375","title":"Artificial Intelligence for Detecting Retinal Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":1000000,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT06769412","title":"A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)","phase":"","overall_status":"COMPLETED","enrollment_count":550000,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04240652","title":"The Diabetic Retinopathy Screening, Prevention and Control Program","phase":"","overall_status":"RECRUITING","enrollment_count":500000,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT07105228","title":"Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study","phase":"","overall_status":"COMPLETED","enrollment_count":290000,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03579797","title":"Shanghai Diabetic Eye Study in Diabetics","phase":"","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"Shanghai Eye Disease Prevention and Treatment Center","has_results":false},{"nct_id":"NCT03479736","title":"A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events","phase":"","overall_status":"COMPLETED","enrollment_count":117911,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05981950","title":"Real-world of AI in Diagnosing Retinal Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT03752840","title":"Village-Integrated Eye Worker Trial II","phase":"NA","overall_status":"RECRUITING","enrollment_count":60200,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06287645","title":"Color Fundus Photograph With Experts Labelling","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Pakistan Council of Scientific and Industrial Research","has_results":false},{"nct_id":"NCT07308639","title":"DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05527535","title":"Expansion of Integrated AI Solution for Diabetic Retinopathy Screening in Thailand","phase":"","overall_status":"UNKNOWN","enrollment_count":34500,"lead_sponsor_name":"Department of Medical Services Ministry of Public Health of Thailand","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05527054","title":"Risk Factors and Machine Learning Model for Diuretics Related Acute Kidney Injury","phase":"","overall_status":"UNKNOWN","enrollment_count":18000,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT06478407","title":"Community Screening Study of Diabetic Retinopathy in Tianjin in 2024","phase":"","overall_status":"RECRUITING","enrollment_count":18000,"lead_sponsor_name":"Li Xiaorong","has_results":false},{"nct_id":"NCT03278587","title":"Village-Integrated Eye Worker Trial II - Pilot","phase":"NA","overall_status":"COMPLETED","enrollment_count":16075,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT07482228","title":"Long-term Clinical Outcomes After Retinal Artery Occlusion","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Chonnam National University Hospital","has_results":false},{"nct_id":"NCT06328075","title":"Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"Algalarrondo Vincent","has_results":false},{"nct_id":"NCT07497815","title":"Artificial Intelligence-assisted Diagnosis in Ophthalmology","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Marisse Masis-Solano","has_results":false},{"nct_id":"NCT04561050","title":"Prediction of Massive Transfusion in Trauma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":13222,"lead_sponsor_name":"Centre Hospitalier Universitaire Vaudois","has_results":false},{"nct_id":"NCT05773495","title":"Implementation of Teleophthalmology in Urban Health Systems Study","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12840,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT04002258","title":"Prolactin Change in Chinese Patients With Schizophrenia After Antipsychotics Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":10363,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT04935749","title":"Epidemiologic Assessment of Diabetic Retinopathy in Egypt Using Ultrawide Field Fundus Photographs","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Alexandria University","has_results":false},{"nct_id":"NCT04592068","title":"AI Classifies Multi-Retinal Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT03665090","title":"Shanghai Cohort Study of Diabetic Eye Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":8000,"lead_sponsor_name":"Shanghai Eye Disease Prevention and Treatment Center","has_results":false},{"nct_id":"NCT07312669","title":"ROP Check Database Premature Infant Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":7070,"lead_sponsor_name":"Alaska Blind Child Discovery","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT00628745","title":"Transthyretin Amyloidosis Outcome Survey (THAOS)","phase":"","overall_status":"COMPLETED","enrollment_count":6718,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT00378742","title":"Repository for Inherited Eye Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":6618,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT02814929","title":"Incidence, Risk Factors and Severity of Retinopathy of Prematurity (ROP) in Turkey","phase":"","overall_status":"COMPLETED","enrollment_count":6115,"lead_sponsor_name":"Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital","has_results":false},{"nct_id":"NCT01109394","title":"Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies","phase":"","overall_status":"RECRUITING","enrollment_count":6035,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05476926","title":"A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06112431","title":"Eye Health Intervention Study in Upper Manhattan","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":5840,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT03237494","title":"TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects","phase":"","overall_status":"COMPLETED","enrollment_count":5028,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT07301112","title":"Transitions and Old Age Potential - 1st, 2nd, and 3rd Wave","phase":"","overall_status":"COMPLETED","enrollment_count":5002,"lead_sponsor_name":"Jacobs University Bremen gGmbH","has_results":false},{"nct_id":"NCT03135327","title":"Clinical Applications of Advanced Ophthalmic Imaging","phase":"NA","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT06729333","title":"A Multicenter and Prospective Study of Screening Retinopathy of Prematurity in China","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT03753893","title":"Ocular Manifestations in Rheumatic Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT07143851","title":"Multi-modal Intelligent Diagnosis System for Multiple Ophthalmic Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Beijing Hospital","has_results":false},{"nct_id":"NCT03094819","title":"PROTECT2: Diabetes Care - Eye Exam","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4500,"lead_sponsor_name":"Retinal Care Inc.","has_results":false},{"nct_id":"NCT06367530","title":"Trilateral Retinoblastoma: Incidence and Outcomes","phase":"","overall_status":"RECRUITING","enrollment_count":4351,"lead_sponsor_name":"Amsterdam UMC, location VUmc","has_results":false},{"nct_id":"NCT07069647","title":"Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics","phase":"NA","overall_status":"RECRUITING","enrollment_count":4300,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06355219","title":"Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines","phase":"","overall_status":"COMPLETED","enrollment_count":3932,"lead_sponsor_name":"Ali Aminian","has_results":false},{"nct_id":"NCT06408571","title":"Study on the Pathogenesis of Retinal Vascular Diseases Based on Body Fluid Metabolomics","phase":"","overall_status":"UNKNOWN","enrollment_count":3900,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT00001310","title":"Tissue Studies of Human Eye Diseases","phase":"","overall_status":"TERMINATED","enrollment_count":3833,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT00231010","title":"Molecular Genetics of Retinal Degenerations","phase":"","overall_status":"COMPLETED","enrollment_count":3549,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT06123923","title":"Trends of Vitreoretinal Surgery in Children","phase":"","overall_status":"COMPLETED","enrollment_count":3509,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05759637","title":"Type 2 Diabetes, Obesity and Cortisol Excess","phase":"","overall_status":"RECRUITING","enrollment_count":3200,"lead_sponsor_name":"Istituto Auxologico Italiano","has_results":false},{"nct_id":"NCT04624737","title":"Intelligent Evaluation of Diabetic Retinopathy","phase":"NA","overall_status":"COMPLETED","enrollment_count":3183,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04425434","title":"Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"French Africa Pediatric Oncology Group","has_results":false},{"nct_id":"NCT03899623","title":"Multi-modal Imaging and Artificial Intelligence Diagnostic System for Multi-level Clinical Application","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}